-
Gilead Sciences Announces Steps to Expand Availability of Remdesivir in India
– Gilead Will Donate a Minimum of 450,000 Vials of Veklury® to the Government of India – – Company Will Continue to Support Expansion of Local Production Capacity – FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead ...
-
-- Data Presented Includes a Comparative Analysis of Clinical Recovery and Mortality Outcomes from the Phase 3 SIMPLE Trial Versus Real-World Cohort of Severe COVID-19 Patients Receiving Standard ...
-
Gilead Announces Approval of Veklury® (remdesivir) in Japan for Patients With Severe COVID-19
-- Exceptional Approval is Based on Data from Global Clinical Trials and Gilead’s Compassionate Use Program -- FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) ...
-
Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19
-- Study Demonstrates 5-Day Treatment Course of Remdesivir Resulted in Significantly Greater Clinical Improvement Versus Treatment with Standard of Care Alone -- -- Data Add to Body ...
-
-- Veklury is the First Approved Treatment Option for COVID-19 in the European Union -- FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European ...
-
-- U.S. FDA Grants Investigational New Drug Authorization to Study Remdesivir for the Treatment of COVID-19 -- FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 26, 2020-- Gilead Sciences, Inc. (Nasdaq: ...
-
-- Authorization Enables Broader Use of Remdesivir to Treat Hospitalized Patients with Severe COVID-19 Disease in the United States -- -- Based on Patients’ Severity of Disease, Authorization ...
-
-- Study Demonstrates Similar Efficacy with 5- and 10-Day Dosing Durations of Remdesivir -- FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline ...
-
-- Remdesivir treatment resulted in clinical improvement in 68 percent of patients in this limited data set -- FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) ...
-
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences. Inc. (Nasdaq: GILD) is aware of positive data emerging from the National Institute of Allergy and Infectious Diseases’ (NIAID) study of the investigational ...